GLP-1 Abdominal Pain: When to Seek Care and How to Report Side Effects in South Africa

What changed in 2026—and where?

On 29 January 2026, the UK Medicines and Healthcare products Regulatory Agency strengthened warnings about acute pancreatitis with GLP-1 and dual GLP-1/GIP medicines, including rare reports of necrotising and fatal cases. It highlighted the difficulty of distinguishing early pancreatitis symptoms from common gastrointestinal effects.¹

This is a UK safety communication, not a new South African recall or a September announcement. Our sources were checked on 14 September 2026. This article is original editorial synthesis, not an interview, a locally measured risk estimate or a clinician-reviewed case report. Ask your South African prescriber or pharmacist to check the current local information for the exact medicine supplied.

Do not diagnose the cause from a symptom label

Pancreatitis is inflammation of the pancreas. The US National Institute of Diabetes and Digestive and Kidney Diseases describes several possible causes, including gallstones, heavy alcohol use and medicines. Assessment can involve medical history, examination, laboratory tests and imaging.² A symptom beginning after a medicine is important information; timing alone does not identify the cause.

For clinicians, the MHRA advises stopping the medicine immediately if pancreatitis is suspected and not restarting it if pancreatitis is confirmed.¹ If you develop the warning symptoms, seek urgent assessment and tell the treating team about GLP-1 use. Do not try to manage suspected pancreatitis by changing a dose yourself.

Our three-part framework: care, context, reporting

Bring the packaging or a clear photograph if readily available, but do not delay urgent care to find it. For the conversation, we suggest noting the exact product name, ingredient and strength on the label; batch and expiry if visible; where it was supplied; when it was last taken; when symptoms began; and other medicines or supplements used. Record what you know and label uncertainty rather than guessing.

Privately prescribed GLP-1 medicines may be absent from a patient’s usual medical record, a gap the MHRA explicitly flags.¹ Tell the treating team directly, even if you expect another practice’s records to be available. A concise timeline is more useful than a confident explanation of an unconfirmed cause.

How South Africans can report a suspected side effect

SAHPRA’s Med Safety service accepts suspected adverse-reaction reports from patients and healthcare professionals. Its instructions say to select South Africa in the app; reports then go to the national pharmacovigilance centre for assessment. You do not have to be a healthcare professional to report.³

1. Address urgent healthcare needs first. Reporting is a separate step.
2. Use the official SAHPRA Med Safety page linked below to find the app and guidance. Select South Africa, not a foreign reporting system.
3. Provide an accurate account of the suspected event and medicine details you have. A pharmacist or clinician can help you organise this information.
4. Keep the acknowledgement and any follow-up information. Do not post identifying medical details in public comments or testimonials.

A report describes a suspicion for assessment; it is not a confirmed diagnosis or proof of causation. Counting reports also cannot, by itself, tell an individual their probability of harm: that would require suitable information about exposure and the people being compared. We have not calculated a South African pancreatitis rate from overseas reports.

Product status is a separate safety question

On 8 July 2026, SAHPRA, the SAPC and the HPCSA warned against continued use or dispensing of recalled iDEXIS semaglutide and tirzepatide products. That notice concerns named recalled products; it should not be confused with the UK class-wide pancreatitis warning.⁴

Evidence and product authorisation answer different questions. Human medicine safety guidance does not establish that a research-labelled compound is authorised, equivalent to a registered product or suitable for self-treatment. Preclinical findings do not fill those gaps; veterinary evidence is not a substitute for human clinical evidence. This article offers no dosing, cycling or supplement-based workaround for a serious adverse reaction.